-
Je něco špatně v tomto záznamu ?
Soluble endoglin modulates the pro-inflammatory mediators NF-κB and IL-6 in cultured human endothelial cells
M. Varejckova, E. Gallardo-Vara, M. Vicen, B. Vitverova, P. Fikrova, E. Dolezelova, J. Rathouska, A. Prasnicka, K. Blazickova, S. Micuda, C. Bernabeu, I. Nemeckova, P. Nachtigal,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- endoglin biosyntéza MeSH
- endoteliální buňky pupečníkové žíly (lidské) metabolismus MeSH
- HEK293 buňky MeSH
- inhibitor diferenciace 1 biosyntéza MeSH
- interleukin-6 biosyntéza MeSH
- lidé MeSH
- NF-kappa B biosyntéza MeSH
- regulace genové exprese * MeSH
- rozpustnost MeSH
- signální transdukce * MeSH
- zánět chemicky indukované metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Endoglin is a transmembrane glycoprotein, that plays an important role in regulating endothelium. Proteolytic cleavage of membrane endoglin releases soluble endoglin (sEng), whose increased plasma levels have been detected in diseases related to the cardiovascular system. It was proposed that sEng might damage vascular endothelium, but detailed information about the potential mechanisms involved is not available. Thus, we hypothesized that sEng contributes to endothelial dysfunction, leading to a pro-inflammatory phenotype by a possible modulation of the TGF-β and/or inflammatory pathways. MAIN METHODS: Human umbilical vein endothelial cells (HUVECs) and Human embryonic kidney cell line (HEK293T) were treated with different sEng concentration and time in order to reveal possible effect on biomarkers of inflammation and TGF-β signaling. IL6 and NFκB reporter luciferase assays, quantitative real-time PCR analysis, Western blot analysis and immunofluorescence flow cytometry were used. KEY FINDINGS: sEng treatment results in activation of NF-κB/IL-6 expression, increased expression of membrane endoglin and reduced expression of Id-1. On the other hand, no significant effects on other markers of endothelial dysfunction and inflammation, including eNOS, peNOS(S1177), VCAM-1, COX-1, COX-2 and ICAM-1 were detected. SIGNIFICANCE: As a conclusion, sEng treatment resulted in an activation of NF-κB, IL-6, suggesting activation of pro-inflammatory phenotype in endothelial cells. The precise mechanism of this activation and its consequence remains to be elucidated. A combined treatment of sEng with other cardiovascular risk factors will be necessary in order to reveal whether sEng is not only a biomarker of cardiovascular diseases, but also a protagonist of endothelial dysfunction.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023183
- 003
- CZ-PrNML
- 005
- 20170831113810.0
- 007
- ta
- 008
- 170720s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lfs.2017.03.014 $2 doi
- 035 __
- $a (PubMed)28336397
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Varejckova, Michala $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 245 10
- $a Soluble endoglin modulates the pro-inflammatory mediators NF-κB and IL-6 in cultured human endothelial cells / $c M. Varejckova, E. Gallardo-Vara, M. Vicen, B. Vitverova, P. Fikrova, E. Dolezelova, J. Rathouska, A. Prasnicka, K. Blazickova, S. Micuda, C. Bernabeu, I. Nemeckova, P. Nachtigal,
- 520 9_
- $a AIMS: Endoglin is a transmembrane glycoprotein, that plays an important role in regulating endothelium. Proteolytic cleavage of membrane endoglin releases soluble endoglin (sEng), whose increased plasma levels have been detected in diseases related to the cardiovascular system. It was proposed that sEng might damage vascular endothelium, but detailed information about the potential mechanisms involved is not available. Thus, we hypothesized that sEng contributes to endothelial dysfunction, leading to a pro-inflammatory phenotype by a possible modulation of the TGF-β and/or inflammatory pathways. MAIN METHODS: Human umbilical vein endothelial cells (HUVECs) and Human embryonic kidney cell line (HEK293T) were treated with different sEng concentration and time in order to reveal possible effect on biomarkers of inflammation and TGF-β signaling. IL6 and NFκB reporter luciferase assays, quantitative real-time PCR analysis, Western blot analysis and immunofluorescence flow cytometry were used. KEY FINDINGS: sEng treatment results in activation of NF-κB/IL-6 expression, increased expression of membrane endoglin and reduced expression of Id-1. On the other hand, no significant effects on other markers of endothelial dysfunction and inflammation, including eNOS, peNOS(S1177), VCAM-1, COX-1, COX-2 and ICAM-1 were detected. SIGNIFICANCE: As a conclusion, sEng treatment resulted in an activation of NF-κB, IL-6, suggesting activation of pro-inflammatory phenotype in endothelial cells. The precise mechanism of this activation and its consequence remains to be elucidated. A combined treatment of sEng with other cardiovascular risk factors will be necessary in order to reveal whether sEng is not only a biomarker of cardiovascular diseases, but also a protagonist of endothelial dysfunction.
- 650 _2
- $a endoglin $x biosyntéza $7 D000071063
- 650 12
- $a regulace genové exprese $7 D005786
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a endoteliální buňky pupečníkové žíly (lidské) $x metabolismus $7 D061307
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x chemicky indukované $x metabolismus $7 D007249
- 650 _2
- $a inhibitor diferenciace 1 $x biosyntéza $7 D051798
- 650 _2
- $a interleukin-6 $x biosyntéza $7 D015850
- 650 _2
- $a NF-kappa B $x biosyntéza $7 D016328
- 650 12
- $a signální transdukce $7 D015398
- 650 _2
- $a rozpustnost $7 D012995
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gallardo-Vara, Eunate $u Center for Biological Research, Spanish National Research Council (CSIC), Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.
- 700 1_
- $a Vicen, Matej $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Vitverova, Barbora $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Fikrova, Petra $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Dolezelova, Eva $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Rathouska, Jana $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Prasnicka, Alena $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Blazickova, Katerina $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Micuda, Stanislav $u Charles University, Faculty of Medicine in Hradec Kralove, Department of Pharmacology, Hradec Kralove, Czech Republic.
- 700 1_
- $a Bernabeu, Carmelo $u Center for Biological Research, Spanish National Research Council (CSIC), Biomedical Research Networking Center on Rare Diseases (CIBERER), Madrid, Spain.
- 700 1_
- $a Nemeckova, Ivana $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic.
- 700 1_
- $a Nachtigal, Petr $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biological and Medical Sciences, Hradec Kralove, Czech Republic. Electronic address: petr.nachtigal@faf.cuni.cz.
- 773 0_
- $w MED00003147 $t Life sciences $x 1879-0631 $g Roč. 175, č. - (2017), s. 52-60
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28336397 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170831114357 $b ABA008
- 999 __
- $a ok $b bmc $g 1238864 $s 984096
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 175 $c - $d 52-60 $e 20170321 $i 1879-0631 $m Life sciences $n Life Sci $x MED00003147
- LZP __
- $a Pubmed-20170720